Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion.

Abstract

This case report evaluated continuous subcutaneous insulin infusion (CSII) in a 50-year-old Caucasian woman who suffered from partial lipodystrophy and severely insulin-resistant diabetes mellitus. Intensive insulin therapy (three daily injections) failed to provide good metabolic control (HbA1c ranging from 10 to 12%). Even though the patient had very thin subcutaneous tissue, CSII was initiated and proved highly efficient, improving blood glucose control considerably (HbA1c ranging from 7.5 to 8.5%), but with no decrease in the daily insulin requirement (2 IU/kg/day). Plasma triglycerides were also greatly improved (from 16.5 to 3.7 mmol/l). Thus, this study indicates that CSII is suitable for patients with lipoatrophy and insulin-resistant diabetes mellitus.

• Authors: L Meyer, S Hadjadj, B Guerci, I Delbachian, O Ziegler, P Drouin
• Journal: Diabetes & metabolism (Diabetes Metab) Vol. 24 Issue 6 Pg. 544-6 (Dec 1998) ISSN: 1262-3636 [Print] France
• PMID: 9932222 (Publication Type: Case Reports, Journal Article)

Chemical References

• Hypoglycemic Agents
• Insulin

Topics

• Adolescent
• Diabetes Mellitus, Lipoatrophic (drug therapy)
• Female
• Follow-Up Studies
• Humans
• Hypoglycemic Agents (therapeutic use)
• Infusions, Parenteral
• Injections, Subcutaneous
• Insulin (therapeutic use)
• Insulin Resistance
• Middle Aged